Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 225

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 225
---
              $ |    729 |   |

| *) | less than 1 thousand |

<div align='center'>The accompanying notes are an integral part
of these financial statements.

F-39</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 1: - GENERAL

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation”).
As a result of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence
as a Nevada corporation under the name “Revium Rx.”

In
November 2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli
company engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following
the closing of such agreement on July 23, 2024, the Predecessor became a wholly owned subsidiary of the Company, and as determined by
the Company’s board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors
determined to discontinue all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making
support system which constituted the business of the Successor prior to the closing of the stock exchange agreement, and to focus on
the development of the acquired LipoVation’s business.

Through
its subsidiary LipoVation Ltd, the Company is developing next-generation, lipid-based therapies to address some of the most pressing
challenges in medicine. Through the subsidiary, the Company is focusing on creating targeted treatments that improve how medicines work
in the body, with the goal of increasing effectiveness while reducing side effects. The pipeline, which is comprised of drug candidates
in various stages of development, includes advanced delivery systems for a variety of indications, including a liposomal antibiotic targeted
at fighting drug-resistant infections and a liposomal therapy designed to boost the impact of cancer treatments.

| b. |     | Liquidity and management 
 plans:                   |

The Company
is in the research and development (R&D) stage and, as such, has not generated any revenues from its current operations. The Company’s
activities are primarily funded through the proceeds of private placement of its securities. As of September 30, 2025